Alzheimer Disease

>

Latest News

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.
FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review

April 3rd 2024

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

research
Have You Seen the Translating Research Into Practice Column?

April 2nd 2024

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.
From the Pages of Psychiatric Times: March 2024

March 30th 2024

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.
The Week in Review: March 11-15

March 16th 2024

FDA
Donanemab Delay: FDA Calls for Last-Minute Meeting to Discuss Safety and Efficacy

March 8th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.